IL33 and kidney disease (Review)

Author：          

Publisher： Spandidos Publications

E-ISSN： 1791-3004|13|1|3-8

ISSN： 1791-2997

Source： Molecular Medicine Reports, Vol.13, Iss.1, 2016-01, pp. : 3-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk of cardiovascular disease in kidney donors as a chronic kidney disease cohort

By              

Molecular Medicine Reports, Vol. 5, Iss. 1, 2012-01 ,pp. : 7-11

Spandidos Publications

Access to resources Recommend Favorite

IL33 levels differentiate tuberculous pleurisy from malignant pleural effusions

By          

Oncology Letters, Vol. 8, Iss. 1, 2014-01 ,pp. : 449-453

Spandidos Publications

Access to resources Recommend Favorite

Light-chain Deposition Disease of the Kidney: A Case Report

By Darouich Sihem   Goucha Rym   Jaafoura Mohamed Habib   Zekri Semy   Kheder Adel   Maiz Hedi Ben  

Ultrastructural Pathology, Vol. 36, Iss. 2, 2012-04 ,pp. : 134-138

Informa Healthcare

Access to resources Recommend Favorite

Amygdalin inhibits renal fibrosis in chronic kidney disease

By          

Molecular Medicine Reports, Vol. 7, Iss. 5, 2013-01 ,pp. : 1453-1457

Spandidos Publications

Access to resources Recommend Favorite

Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?

By Kirkali Ziya   Tüüzel Emre  

Future Oncology, Vol. 5, Iss. 6, 2009-08 ,pp. : 871-888

Future Medicine

Access to resources Recommend Favorite